Primary aldosteronism: diagnostic and treatment strategies (Q36577140)

15 August 2017

1 reference

title

Primary aldosteronism: diagnostic and treatment strategies (English)

1 reference

15 August 2017

Cecilia Mattsson

1

1 reference

15 August 2017

William F Young

series ordinal

2

1 reference

15 August 2017

publication date

1 April 2006

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

198-208; quiz, 1 p following 230

1 reference

Outpatient screening tests for primary aldosteronism

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Levels of mineralocorticoids in whites and blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Aldosterone induces a vascular inflammatory phenotype in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Diagnosis and treatment of primary hyperaldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Adverse cardiac effects of salt with fludrocortisone in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Captopril suppression versus salt loading in confirming primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Primary aldosteronism: factors associated with normalization of blood pressure after surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Prevalence of primary and secondary hypertension: studies in a random population sample.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Reliability of screening methods for the diagnosis of primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Primary aldosteronism and hypertensive disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

High incidence of primary aldosteronism in 199 patients referred with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

High prevalence of primary aldosteronism in the Tayside hypertension clinic population.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Hyperaldosteronism among black and white subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

NORMOKALEMIC PRIMARY ALDOSTERONISM. A DETECTABLE CAUSE OF CURABLE "ESSENTIAL" HYPERTENSION

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Aldosterone and end-organ damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Remodeling of the rat right and left ventricles in experimental hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Prevalence and characteristics of the metabolic syndrome in primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Hyperparathyroidism and the calcium paradox of aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Genetics of primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Primary aldosteronism - treatment options

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

The current epidemic of primary aldosteronism: causes and consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

The diagnosis of primary aldosteronism and separation of two major subtypes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Primary aldosteronism--careful investigation is essential and rewarding

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Adrenal incidentaloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Role for adrenal venous sampling in primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Location of Aldosterone-Producing Adenomas with131I-19-Iodocholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

From needles to numbers: can noninvasive imaging distinguish benign and malignant adrenal lesions?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Familial hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Long-term follow-up after adrenalectomy for primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Factors influencing outcome of surgery for primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Primary aldosteronism. Results of surgical treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Laparoscopic adrenalectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Adrenal lesions assessed in the era of laparoscopic adrenalectomy: a modern day series

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Trends in utilization of adrenalectomy in the United States: have indications changed?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Medical management of aldosterone-producing adenomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Efficacy and tolerance of spironolactone in essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Human endothelium: target for aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Glucocorticoid-remediable aldosteronism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0151

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0151

1 reference

Dimensions Publication ID

15 August 2017

1000062772

0 references

1 reference